Chemistry:Navacaprant
From HandWiki
Short description: Investigational antidepressant compound
 | |
| Clinical data | |
|---|---|
| Other names | BTRX-140; CYM-53093; NMRA-140 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H32FN5O2 |
| Molar mass | 453.562 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is an opioid antagonist medication which is under development for the treatment of depression.[1][2][3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder.[1][2][3] As of February 2020, BTRX-335140 is in phase 2 clinical trials for this indication.[2]
See also
- κ-Opioid receptor § Antagonists
- List of investigational antidepressants
References
- ↑ 1.0 1.1 "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders" (in en). https://www.blackthornrx.com/publications/blackthorn-therapeutics-advances-phase-2-clinical-development-for-selective-kor-antagonist-btrx-140-in-neuropsychiatric-disorders/.
- ↑ 2.0 2.1 2.2 "BTRX 335140 - AdisInsight". https://adisinsight.springer.com/drugs/800054451.
- ↑ 3.0 3.1 "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. February 2019. doi:10.1021/acs.jmedchem.8b01679. PMID 30707578.
External links
 |  |
